PHS Act Section 351(k) - Biosimilars Licensure Pathway

What it says

A biological product may be licensed as biosimilar to, or interchangeable with, a reference product through an abbreviated pathway that relies in part on demonstrating high similarity to the already-licensed reference product, rather than requiring a complete independent set of clinical data as with a standard biologics license application.

Paraphrased for plain-language clarity. Always verify against the current published regulation text.

What it means in practice

• A biosimilar manufacturer must still fully satisfy its own independent CGMP manufacturing requirements, the abbreviated pathway relates to the clinical and analytical similarity showing, not to manufacturing quality obligations.
• Analytical similarity data supporting a biosimilar submission depends heavily on well-controlled, validated analytical methods, connecting this pathway closely to the method validation principles in ICH Q2(R2) and comparability concepts.
• Because interchangeable status permits substitution at the pharmacy level without prescriber intervention in many jurisdictions, maintaining consistent manufacturing and quality control is particularly important for interchangeable products.

What FDA inspectors look for

• Whether the biosimilar manufacturer's own CGMP systems are fully established and independent of the reference product manufacturer's systems.
• Whether analytical comparability data supporting biosimilarity claims was generated using validated, well-controlled methods.
• Whether manufacturing process changes made after licensure were evaluated for their potential impact on the demonstrated biosimilarity to the reference product.

Related regulations